Hosted on MSN2mon
Eli Lilly to acquire Scorpion for up to $2.5B
Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine.
Hosted on MSN2mon
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Shares of Eli Lilly were down 1.7% in midday trade. As part of the deal, Eli Lilly will acquire Scorpion's STX-478, an investigative once-daily oral medication being evaluated in a trial.
pharmaphorum5d
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...